Vipul Jairath
University of Western Ontario
311 Papers
250 Citations
Vipul Jairath is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 35, co-authored 88 publications. Previous affiliations of Vipul Jairath include NHS Blood and Transplant & University of Oxford.
Chat about Author
Papers
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
Amanda M. Johnson,Maria Barsky,Waseem Ahmed,Samantha Zullow,Jonathan S. Galati,Vipul Jairath,Neeraj Narula,Farhad Peerani,Benjamin H. Click,Elliot Coburn,ThucNhi T. Dang,Stephanie Gold,Manasi Agrawal,Rajat Garg,Manik Aggarwal,D Mohammad,Brendan P. Halloran,Gursimran Kochhar,Hannah Todorowski,Nabeeha Mohy Ud Din,James L. Izanec,Amanda Teeple,Christopher Gasink,Erik Muser,Zhijie Ding,Arun Swaminath,Komal Lakhani,Daniel T. Hogan,Samit K. Datta,Ryan C. Ungaro,Brigid S. Boland,Matthew Bohm,Monika Fischer,Sashidhar Sagi,Anita Afzali,Thomas A. Ullman,Garrett Lawlor,Daniel C. Baumgart,Shan Tzu Chang,David Hudesman,Dana J. Lukin,Ellen Scherl,Jean-Frederic Colombel,Bruce E. Sands,Corey A. Siegel,Miguel Regueiro,William J. Sandborn,David H. Bruining,Sunanda V. Kane,Edward V. Loftus,Parambir S. Dulai +50 more
TL;DR: The greatest treatment effect of UST was seen in bio-naive patients, and dose escalation may recapture clinical response, with 40% of patients from a highly refractory cohort achieving clinical remission by 12 months.
40
Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease
Neeraj Narula,Emily C L Wong,Parambir S. Dulai,John C. Marshall,Vipul Jairath,Walter Reinisch +5 more
TL;DR: TNF-α antagonists were overall superior to vedolizumab and ustekinumab for achieving 1-year EH in moderate-severe Crohn's disease patients.
40
Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey
Christopher Ma,Remo Panaccione,Richard N. Fedorak,Claire E Parker,Reena Khanna,Barrett G. Levesque,William J. Sandborn,Brian G. Feagan,Vipul Jairath +8 more
TL;DR: Standardising outcomes through a COS will reduce heterogeneity in trial reporting, facilitate valid comparisons of new therapies and improve clinical trial quality.
39
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview
Pieter Hindryckx,Pieter Hindryckx,Gregor Novak,Gregor Novak,Niels Vande Casteele,Niels Vande Casteele,Reena Khanna,Debby Laukens,Vipul Jairath,Brian G. Feagan +9 more
TL;DR: A greater understanding of the pharmacokinetics of therapeutic antibodies has led to the development of new strategies to reduce immunogenicity and more efficient use ofThese preventive strategies include regular scheduled dosing with maintenance of stable therapeutic trough drug concentrations, and co-administration of an immunosuppressive.
Anticoagulation in patients with liver cirrhosis: complication or therapeutic opportunity?
TL;DR: Thrombin generation is regulated by the anticoagulant system, including proteins C, S and antithrombin, and clot dissolution occurs via activation of the fibrinolytic cascade, thus preventing bleeding or thrombotic complications.
38